Prurigo Nodularis Market

Market Overview:

The 7 major prurigo nodularis markets are expected to exhibit a CAGR of 3.07% during 2024-2034.

The prurigo nodularis market has been comprehensively analyzed in IMARC's new report titled "Prurigo Nodularis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Prurigo nodularis refers to a medical condition characterized by the presence of intensely itchy, firm, and raised nodules on the skin's surface. It is a chronic disorder that can persist for an extended period. The primary symptom of this illness is intense itching, which often leads to a vicious itch-scratch cycle, exacerbating the condition and causing the nodules to grow larger and more prominent over time. These nodules may be red, black, or brown in color and might range in size from a few millimeters to a few centimeters. The indications can have a significant psychological impact on some patients, leading to anxiety, depression, or sleep disturbances. The diagnosis of prurigo nodularis is usually made based on the characteristic appearance of the nodules and the history of persistent itching and scratching. In addition to this, patch testing may be conducted to identify any contact allergens that could be contributing to the disease. A healthcare provider may also perform a skin biopsy, followed by a microscopic examination, to confirm the diagnosis.

The increasing prevalence of pruritus that can be triggered by various underlying conditions, such as eczema, insect bites, skin inflammation, etc., is primarily driving the prurigo nodularis market. In addition to this, the escalating cases of neurological disorders, causing abnormalities in the nerves related to sensation and itching, are also creating a positive outlook for the market. Moreover, the widespread adoption of topical immunomodulators, like tacrolimus and pimecrolimus, which work by modifying or regulating the immune response of the body to decrease inflammation in the affected area, is further bolstering the market growth. Apart from this, the inflating application of light therapy, since it helps to improve the appearance of the skin, reduce the size of nodules, and enhance the quality of life for patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intralesional corticosteroid injections, which offer a more acceptable and tolerable treatment option for patients who are unwilling to take oral medications or apply topical therapies regularly, is expected to drive the prurigo nodularis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the prurigo nodularis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for prurigo nodularis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the prurigo nodularis market in any manner.

Recent Developments:

• In March 2024, Incyte announced the findings of a Phase 2 research assessing the efficacy and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adult patients with prurigo nodularis. After 16 weeks of treatment, all dose groups in a randomized Phase 2 research fulfilled their primary and secondary objectives, highlighting the potential usefulness of povorcitinib in treating prurigo nodularis.
• In February 2024, Galderma announced that the U.S. FDA had approved its Biologics License Applications for nemolizumab for the treatment of prurigo nodularis, as well as for adolescents and adults with moderate to severe atopic dermatitis. Nemolizumab is a first-in-class experimental monoclonal antibody specifically intended to suppress IL-31 signaling, providing safe and quick relief from the most bothersome symptom of both skin conditions: itching.
• In October 2023, Trevi Therapeutics revealed the 52-week findings of Haduvio's phase 2b/3 PRISM open-label extension (OLE) project for the treatment of prurigo nodularis.

Key Highlights:

• Prurigo nodularis is 3.4 times more frequent among African Americans.
• It is more common among HIV patients.
• The annual incidence of prurigo nodularis in the United States is estimated to be 72 per 100,000 persons or 87,634 people between the ages of 18 and 64.
• Prurigo nodularis is more common in the elderly and women (54.2%) than in males (45.5%), with women suffering from more severe pruritus.
• Prurigo nodularis can develop at any age, however it is most common between the ages of 40 and 69.

Drugs:

Vixarelimab (KPL-716) is being developed by Genentech USA for the treatment of prurigo nodularis. It is a completely human monoclonal antibody that targets a single epitope. The medication candidate is delivered both intravenously and subcutaneously. It functions by targeting oncostatin M receptor beta.

Ruxolitinib phosphate (Opzelura) is an anti-neoplastic, immunomodulating, and anti-inflammatory drug. It is developed as a cream for topical use. Incyte is developing Opzelura for prurigo nodularis, which is currently in phase III trials.

CDX-0159 is a humanized monoclonal antibody that binds to the receptor tyrosine kinase KIT with excellent specificity and substantially suppresses its activity. KIT can be identified in a variety of cells, especially mast cells, which drive inflammatory responses such as hypersensitivity and allergies.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the prurigo nodularis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the prurigo nodularis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current prurigo nodularis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the prurigo nodularis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the prurigo nodularis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the prurigo nodularis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of prurigo nodularis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of prurigo nodularis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of prurigo nodularis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with prurigo nodularis across the seven major markets?
• What is the size of the prurigo nodularis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of prurigo nodularis?
• What will be the growth rate of patients across the seven major markets?
   

Prurigo Nodularis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for prurigo nodularis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the prurigo nodularis market?
• What are the key regulatory events related to the prurigo nodularis market?
• What is the structure of clinical trial landscape by status related to the prurigo nodularis market?
• What is the structure of clinical trial landscape by phase related to the prurigo nodularis market?
• What is the structure of clinical trial landscape by route of administration related to the prurigo nodularis market?